| HOME >> MEDICINE >> TECHNOLOGY |
SAN MATEO, Calif., Feb. 9, 2011 /PRNewswire/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced it will hold a conference call on February 14, 2011 at 4:30 p.m. ET (1:30 p.m. PT) to provide an update on the U.S. commercial launch of Qutenza® (capsaicin) 8% patch for the management of neuropathic pain associated with postherpetic neuralgia (PHN).
NeurogesX will highlight key metrics for tracking U.S. physician adoption during the three month period ended December 31, 2010, approximately one month prior to filing fourth quarter 2010 financial results.
The conference call will be hosted by Anthony DiTonno, President and Chief Executive Officer, and Stephen Ghiglieri, Executive Vice President, Chief Operating Officer and Chief Financial Officer.
To participate, please dial 1-877-407-0789 (USA) or 1-201-689-8562 (International). To access the live web cast please visit the Investor Relations section on the corporate web site at http://www.neurogesx.com.
A replay of the conference call will be available beginning February 14, 2011 at 8:00 p.m. ET (5:00 p.m. PT) and ending on February 24, 2011 by dialing 1-877-870-5176 (USA) or 1-858-384-5517 (International) with Conference ID Number: 367175. A replay of the webcast will also be available on the corporate website through March 14, 2011.
The call will be webcast live and archived for 90 days on the investor relations section of NeurogesX' website at www.neurogesx.com.
About NeurogesX, Inc.
NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and co
'/>"/>
| SOURCE NeurogesX, Inc. Copyright©2010 PR Newswire. All rights reserved |